- Home
- FTDR vs RNA Comparison
FTDR vs RNA Comparison
Compare FTDR & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTDR
- RNA
- Stock Information
- Founded
- FTDR 1971
- RNA 2012
- Country
- FTDR United States
- RNA United States
- Employees
- FTDR N/A
- RNA N/A
- Industry
- FTDR Diversified Commercial Services
- RNA Biotechnology: Pharmaceutical Preparations
- Sector
- FTDR Finance
- RNA Health Care
- Exchange
- FTDR Nasdaq
- RNA Nasdaq
- Market Cap
- FTDR 4.4B
- RNA 4.0B
- IPO Year
- FTDR 2018
- RNA 2020
- Fundamental
- Price
- FTDR $66.66
- RNA $45.60
- Analyst Decision
- FTDR Hold
- RNA Strong Buy
- Analyst Count
- FTDR 4
- RNA 14
- Target Price
- FTDR $59.75
- RNA $69.86
- AVG Volume (30 Days)
- FTDR 639.7K
- RNA 3.1M
- Earning Date
- FTDR 11-03-2025
- RNA 11-06-2025
- Dividend Yield
- FTDR N/A
- RNA N/A
- EPS Growth
- FTDR 29.61
- RNA N/A
- EPS
- FTDR 3.36
- RNA N/A
- Revenue
- FTDR $1,966,000,000.00
- RNA $10,729,000.00
- Revenue This Year
- FTDR $14.54
- RNA N/A
- Revenue Next Year
- FTDR $6.49
- RNA $110.16
- P/E Ratio
- FTDR $20.00
- RNA N/A
- Revenue Growth
- FTDR 8.62
- RNA 1.23
- 52 Week Low
- FTDR $35.61
- RNA $21.51
- 52 Week High
- FTDR $67.23
- RNA $56.00
- Technical
- Relative Strength Index (RSI)
- FTDR 68.25
- RNA 52.23
- Support Level
- FTDR $63.31
- RNA $35.70
- Resistance Level
- FTDR $67.26
- RNA $49.16
- Average True Range (ATR)
- FTDR 2.00
- RNA 2.63
- MACD
- FTDR 0.51
- RNA -0.81
- Stochastic Oscillator
- FTDR 95.23
- RNA 63.79
About FTDR Frontdoor Inc.
Frontdoor Inc is a United States-based company that provides home service plans. It owns multiple home service brands including American Home Shield, HSA, OneGuard, and Landmark brands. Through its home service plans, the company helps its customers maintain their homes and protect against costly and unexpected breakdowns of essential home systems and appliances.
About RNA Avidity Biosciences Inc.
Avidity Biosciences Inc is a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, or AOCs. Company's pipeline currently has three programs in potentially registrational clinical trials: DM1, FSHD, and DMD. The segments includes following: Del-zota for DMD44, Del-desiran for DM1, Del-brax for FSHD.